Evidence map›Paper›PMID 27687681›Full record

Trial reportUrolithiasis2017

Comparison of escalating, constant, and reduction energy output in ESWL for renal stones: multi-arm prospective randomized study.

Danny M Rabah, Mohamed S Mabrouki, Karim H Farhat, Mohamed A Seida, Mostafa A Arafa, Riyadh F Talic

Abstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Urolithiasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Danny M RabahSurgery Department, Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Mohamed S MabroukiSurgery Department, Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Karim H FarhatCancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia. kfarhat@ksu.edu.sa.
Mohamed A SeidaSharjah University Hospital, Sharjah, United Arab Emirates.
Mostafa A ArafaCancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Riyadh F TalicSurgery Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was designed to find out the optimized energy delivery strategy in Shock Wave Lithotripsy (SWL) that yield to the best stone-free rate (SFR). In this clinical trial, 150 consecutive patients were randomized into three groups: (a) Dose escalation, 1500 SW at 18 kV, followed by 1500 SW at 20 kV then 1500 SW at 22 kV. (b) Constant dose, 4500 SW at 20 kV. All patients undergo plain X-ray film of the urinary tract at day 1, 14, and 90 to assess stone-free rate (SFR) which was defined as no stones or painless fragments less than 4 mm. (c) Dose reduction, 1500 SW at 22 kV, followed by 1500 SW at 20 kV and then 1500 SW at 18 kV. The three treatment groups were comparable in terms of age, sex, stone size and distribution of the kidneys, and the need for Double J stent use. On day 90, the SFR achieved was 82, 90, and 84 % in the escalating, constant, and reduction energy groups, respectively. However, this rate was not statistically significant (x

Indexed as

AdultDose-Response Relationship, RadiationFemaleHigh-Energy Shock WavesHumansKidneyKidney CalculiLithotripsyMaleMiddle AgedProspective StudiesStentsTreatment OutcomeUreterDose constantDose escalatingDose reductionRenal stonesShock wave lithotripsyStone-free rate

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.